LGC’s Post

Today, we celebrate women all around the world and the magnificent contributions they have made and will continue to make. BPGbio Inc. is committed to developing new therapeutics and diagnostics for the treatment of breast cancer in women. Currently, in partnership with the U.S. Department of Defense, we are developing a new breast cancer diagnostic test focused on increasing survival. This is a 34 gene panel test to “upstage” breast cancer patients so women are treated most effectively at time of diagnoses, thereby potentially leading to better disease outcomes, and saving more lives. You can find more information about our DoD partnership here: https://lnkd.in/gPZUGbcb More information about our in-development breast cancer diagnostic can be found here: https://lnkd.in/d4fpspFw #breastcancer #diagnostics #ai #womensday #departmentofdefense #breastcancertreatment #breastcancerscreening

A recent study by Le Compte et al. illustrates how RNA-Seq can be used to characterize organoids as models for cancer treatment and identify intra-patient response heterogeneity in pancreatic ductal adenocarcinoma, one of the most lethal cancers. RNA-Seq provides a powerful tool that can be used to study gene expression in organoids, and allows identification of genes that are associated with #cancer progression and #drug resistance to develop new therapies for pancreatic cancer in the future. Read the full article: https://lnkd.in/dKCtY5XT 🚀 Ready to start your #RNAseq experiments for #organoids? ⭐ Lexogen is your trusted #NGS partner for drug discovery workflows and cancer models. 💰 Save up to 50% with limited service offer until the end of 2024! Go here for all details: https://lnkd.in/gtrYYC8D #DrugDiscovery #GeneExpression

September 2024 marks the Blood Cancer Awareness Month. As professionals in the health care system for tumor diagnostics, we are aware of the importance of having reliable diagnostic tools. Blood cancer is diagnosed in over 1 million patients every year and describes more than 100 different types of cancer that affect the production and function of blood cells.  With increasing knowledge of different tumor classes in blood cancer comes the demand for more specified molecular diagnostic methods. Many subtypes of blood cancer can be diagnosed by testing for certain genetic alterations. Fluorescence in situ hybridization (FISH) is one of the most reliable methods to detect such gene alterations allowing for tumor classification and individual therapy decisions.     ZytoVision’s FISH portfolio includes over 60 probes that are routinely used to aid blood cancer diagnostics all over the world.     #bloodcancer #bloodcancerawareness #ThisIsBloodCancer

For over 2 decades, cancer therapies have focused on inhibiting oncogenes. Yet many oncogenes are vulnerable not just to inhibition but also to activation – we call this surprising vulnerability ‘activation lethality.’ When oncogenes are overactivated, they overload cell stress pathways, and drugs that overactivate #cancer targets are selectively lethal to cancers with mutations that push them near the limits of tolerable pathway activity. Delphia’s approach integrates #tumor genetics, innovative functional genomic techniques, and studies on inhibitor drug resistance to identify targets that drive #activationlethality. You can learn more at https://lnkd.in/gY2bTe4R.

Today we are excited to present new data highlighting MammaPrint® and Blueprint® for patients with early-stage breast cancer at San Antonio Breast Cancer Symposium (SABCS)! The new real-world evidence findings add to the growing body of data validating the utility of MammaPrint® and Blueprint® for early-stage breast cancer treatment. A gene expression analysis from the FLEX Study, presented in a poster spotlight, reveals MammaPrint® as an available genomic signature that may identify patient subgroups with potential resistance to CDK4/6 inhibition. To learn more, visit: https://lnkd.in/gykyyg6J

#cancerresearch #oncology Hereditary cancer syndrome A syndrome associated with #inherited #susceptibility to #cancer caused by a pathogenic variant in a gene (such as BRCA1 and BRCA2 tumor suppressor genes). Carriers are at high risk for the development of tumors at an early age and generally require close surveillance. The most common hereditary cancer syndromes affect mismatch-repair genes (conferring a predisposition to endometrial cancer and colon cancer) and the homologous-recombination genes BRCA1 and BRCA2 (conferring a predisposition to familial breast, ovarian, prostate, and pancreatic cancer).

Faster Results for Clinicians Treating Breast Cancer Patients Waiting for test results can be a big setback in clinical cancer care, especially if preventative treatment may be urgently required. The Everything Genetic 12 Gene Breast Cancer Panel is delivered from a UK laboratory, allowing you to receive clinically actionable results in just 2–3 weeks. This allows you to quickly determine best next steps for treatments and implement the right preventative care for your patients. By identifying the disease-causing variant, the 12 Gene Breast Cancer Panel can also guide testing and management of at-risk relatives. Find out more: https://buff.ly/3xbhT8d Listen what our Medical Director, Dr James Mackay, has to say about this test in the video below ⬇️ #BreastCancer #BreastCancerTest #GeneticTestForBreastCancer #12GenePanel #UKGeneticTest #GeneticTesting #NGSTesting #GeneticTest #BreastCancerRiskTest #BreastCancerRisk #CancerPrevention #CancerTreatment #CancerDiagnosis

📍 Immunosuppressive pathways associated with metastatic breast cancer Ozmen et al. analyzed the complex landscape of primary and metastatic breast cancer using scRNA-seq to elucidate the mechanisms underlying changes in the metastatic tumor ecosystem. Key findings 📍 CCL2+ macrophages, cytotoxic T cells with an exhausted gene signature, and FOXP3+ regulatory T cells critical to forming a pro-tumor microenvironment in metastatic lesions 📍 A marked decrease in tumor-immune cell interactions in metastatic tissues, likely strengthening the immunosuppressive microenvironment 📍 Increased activation of the TNF-α signaling pathway via NF-kB in primary breast cancer, indicating a potential therapeutic target. ➡ More details: https://lnkd.in/ez-hRwti #OregonHealthandScienceUniversity #spatialomics #spatialbiology #singlecellanalysis #singlecell

This is it. If you’ve ever lost sleep over breast cancer. This is it. If you’re someone with a family history of breast cancer. If you’re someone with a genetic predisposition to breast cancer. If you’re someone with dense breasts. This is it. If you’re someone who believes in unlocking the quality-of-life preservation that exists at the earliest stages of breast cancer. This is it. If you’ve been following our journey. If you’ve been wondering how to get involved. This is it. Mammogen is ushering in the next century’s worth of impact in breast health. Help us help you. Click the link. Get involved. Be the change. This is it.